Jade Biosciences, Inc.
About Jade Biosciences, Inc.
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$127.4M
- Total assets
- $349.8M
- Market cap
- $1.0B
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $113.5M
- Operating income
- -$113.5M
- Income tax
- $58.0K
- Net income
- -$127.4M
- EPS (basic)
- $-3.19
- EPS (diluted)
- $-3.19
Balance sheet
- Total assets
- $349.8M
- Current assets
- $348.8M
- Total liabilities
- $17.3M
- Current liabilities
- $16.5M
- Shareholders’ equity
- $332.5M
Cash flow
- Operating cash flow
- -$94.7M
- Investing cash flow
- -$247.0M
- Financing cash flow
- $360.8M
- Net cash flow
- $19.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.0B
- EPS (diluted)
- $-3.19
- Shares outstanding
- 65.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 29, 2025
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $127.4M.
- Trading 43% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Jade Biosciences, Inc..
Write a review
News about Jade Biosciences, Inc.
News & sentiment via Polygon.io
